Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;2000(2):CD002038.
doi: 10.1002/14651858.CD002038.

Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults

J Darbyshire  1 , M Foulkes, R Peto, W Duncan, A Babiker, R Collins, M Hughes, T Peto, A Walker
Affiliations

Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults

J Darbyshire et al. Cochrane Database Syst Rev. 2000.

Update in

Abstract

Background: Zidovudine (AZT) monotherapy was the first antiretroviral drug to be tested widely. The next two drugs to be developed were didanosine (ddI) and zalcitabine (ddC).

Objectives: To assess the effects of zidovudine (AZT), zidovudine plus didanosine (ddI) and zidovudine plus zalcitabine (ddC) on HIV disease progression and survival.

Search strategy: Investigators and pharmaceutical companies were contacted, and MEDLINE searches were supplemented by searching conference abstracts.

Selection criteria: Randomised controlled trials comparing any two of AZT plus ddI, AZT plus ddC or AZT alone in participants with or without AIDS which collected information on deaths and new AIDS events.

Data collection and analysis: Individual patient data with, wherever possible, follow-up obtained beyond that previously published were obtained and checked for internal consistency and consistency with any published reports; any apparent discrepancies were resolved with the trialists. Time to death and to disease progression (defined as a new AIDS-defining event or prior death) were analysed on an intention to treat basis, stratified to avoid direct comparisons between participants in different trials.

Main results: Six trials were included in the meta-analysis. During a median follow-up of 29 months, 2904 individuals progressed, of whom 1850 died. The addition of ddI to AZT delayed both progression (RR 0.74; 95% CI 0.67 to 0.82, P<0.0001) and death (RR 0.72; 95% CI 0.64 to 0.82, P<0.0001). Likewise, the addition of ddC to AZT also delayed progression (RR 0. 86; 95% CI 0.78 to 0.94, P=0.001) and death (RR 0.87; 95% CI 0.77 to 0.98, P=0.02). After 3 years the estimated percentages alive and without a new AIDS event were 53% for AZT+ddI, 49% for AZT+ddC and 44% for AZT alone; the percentages alive were 68%, 63% and 59% respectively. Five of the six trials involved randomised comparisons of AZT+ddI versus AZT+ddC: in these, the AZT+ddI regimen had greater effects on disease progression (P=0.004) and death (P=0.009).

Reviewer's conclusions: The use of ddI and, to a lesser extent, ddC delayed both HIV disease progression and death, at least when added to AZT.

PubMed Disclaimer

Conflict of interest statement

There is no known conflict of interest.

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

ACTG 155 {unpublished data only}
    1. Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995;122:24‐32. - PubMed
ACTG 175 {unpublished data only}
    1. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV‐infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Eng J Med 1996;335:1081‐1090. - PubMed
ACTG 193A {unpublished data only}
    1. Henry WK, Erice A, Tierney C, Balfour HH, Fischl MA, Kmack A et al for the ACTG 193A Study Team. A randomized, controlled double‐blind study comparing the survival benefit of four different reverse transciptase inhibitor therapies (three‐drug, two‐drug, and alternating drug) for the treatment of advanced AIDS. J Acquir Imm Syndr Hum Ret 1998;19:339‐349. - PubMed
CPCRA 007 {unpublished data only}
    1. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV‐infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Eng J Med 1996;335:1099‐1106. - PubMed
DELTA {unpublished data only}
    1. Delta Coordinating Committee. Delta: a randomised double‐blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV‐infected individuals. Lancet 1996;348:283‐291. - PubMed
GW Resistance {unpublished data only}
    1. Schooley RT, Ramirez‐Ronda C, Lange JMA, Cooper DA, Lavelle J, et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Journal of Infectious Diseases 1996;173:1354‐1366. - PubMed

References to studies excluded from this review

SV 14604 {published data only}
    1. SV14604 Executive Summary (June 18, 1997).

Additional references

Abrams 1994
    1. Abrams DI, Goldman AI, Launer C, Korvick JA, Neaton JD, Crane LR, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Eng J Med 1994;330:657‐663. - PubMed
CAESAR 1997
    1. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV‐1 infection: the CAESAR trial. Lancet 1997;349:1413‐1421. - PubMed
CDC 1987
    1. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36(suppl 1S):1‐15. - PubMed
Dickersin 1996
    1. Dickersin K, Larson K. Establishing and maintaining an international register of RCTs. The Cochrane Collaboration Handbook, Oxford: The Cochrane Collaboration, 1995. Available in: The Cochrane Library, Oxford: Update Software, 1996. Updated quarterly.
EBCTCG 1990
    1. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer: Worldwide evidence 1985‐1990. Oxford University Press, 1990.
Fischl 1987
    1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS‐related complex. A double‐blind, placebo‐controlled trial. N Eng J Med 1987;317:185‐191. - PubMed
Follansbee 1993
    1. Follansbee S, Drew L, Olson R, Pollard R, Reiter W, Salgo M, et al. The efficacy of zalcitabine (ddC, Hivid) versus zidovudine (ZDV) as monotherapy in ZDV naive patients with advanced HIV disease: a randomized, double‐blind, comparative trial (ACTG 114; N3300) [abstract PO‐B26‐2113, p487]. In: Program of the 9th International Conference on AIDS. Vol. N3300) [abstract PO‐B26‐2113, p487]. In:Program of the 9th International Conference on AIDS. Berlin, June 1993.
Hammer 1997
    1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Eng J Med 1997;337(11):725‐733. - PubMed
Montaner 1998
    1. Montaner JSG, Hogg R, Raboud J, Harrigan R, O’Shaughnessy. Antiretroviral treatment in 1998. Lancet 1998;352:1919‐22. - PubMed
Staszewski 1997
    1. Staszewski S, Hill AM, Bartlett J, Eron JJ, Katlama C, Johnson J, Sawyer W, McDade H. Reductions in HIV‐1 disease progression for zidovudine/lamivudine relative to control treatments: a meta‐analysis of controlled trials. AIDS 1997;11:477‐483. - PubMed
Volberding 1994
    1. Volberding PA, Graham NMH. Initiation of antiretroviral therapy in HIV infection: a review of interstudy consistencies. J Acquir Immune Defic Syndr 1994;7:S12‐S23. - PubMed

References to other published versions of this review

HIVTCG 1999
    1. HIV Trialists' Collaborative Group. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta‐analyses of the randomised evidence. Lancet 1999;353:2014‐25. - PubMed

Publication types